Karen R. Jacobson, MD, MPH
Assistant Professor
Boston University School of Medicine
Dept of Medicine
Infectious Diseases

MD, Johns Hopkins University School of Medicine
MPH, Harvard School of Public Health




Dr. Karen Jacobson is an Assistant Professor of Medicine in the Section of Infectious Diseases, Boston University School of Medicine, with a secondary appointment in the Department of Epidemiology, Boston University School of Public Health. Dr. Jacobson’s research focuses on the epidemiology of drug resistant tuberculosis, including identification of social, biological, and economic determinants of and risk factors for drug resistance and approaches for improving TB outcomes in resource-limited settings. Dr. Jacobson has established a highly productive collaboration with researchers at Stellenbosch University in Cape Town, South Africa, investigating the drivers of drug resistance in the Western Cape Province of South Africa and working to identify potentially modifiable factors.

Assistant Professor
Boston University School of Public Health
Epidemiology





Providence/Boston Center for AIDS Research(CFAR): HIV-TB SWG
07/01/2018 - 06/30/2023 (PI)
Miriam Hospital NIH-NIAID

The impact of alcohol consumption on TB treatment outcomes
04/08/2016 - 03/31/2021 (PI)
NIH-NIAID
5R01AI119037-02

URBAN ARCH (3/5) Uganda Cohort- TB prevention therapy for HIV-infected alcohol drinkers in Uganda…
09/22/2016 - 08/31/2019 (PI)
The Regents of the University of California NIH-NIAAA

ASTMH Fellowship in Tropical Infectious Diseases
02/01/2013 - 11/30/2018 (PI)
American Society of Tropical Medicine and Hygiene

Phase 2 Pharmacodynamic Study of Hidh-dose Levofloxacin in MDR-TB Treatment
01/01/2015 - 07/31/2018 (PI)
Trustees of Boston University NIH-NIAID

Lifespan/Tufts/Brown Center for AIDS Research(CFAR): SWG1
07/01/2017 - 06/30/2018 (PI)
Miriam Hospital NIH-NIAID

Geospatial clustering and molecular and social epidemiology of drug resistant TB
08/01/2013 - 12/31/2016 (PI)
NIH-FIC
5K01TW009213-6



Yr Title Project-Sub Proj Pubs
2019 The impact of alcohol consumption on TB treatment outcomes 5R01AI119037-04 2
2018 The impact of alcohol consumption on TB treatment outcomes 5R01AI119037-03 2
2018 SWG1: HIV/TB Scientific Working Group 2P30AI042853-20A1-7401 821
2017 The impact of alcohol consumption on TB treatment outcomes 5R01AI119037-02 2
2016 The impact of alcohol consumption on TB treatment outcomes 1R01AI119037-01A1 2
2015 Geospatial clustering and molecular and social epidemiology of drug resistant TB 5K01TW009213-06 10
2014 Geospatial clustering and molecular and social epidemiology of drug resistant TB 5K01TW009213-05 10
2013 Geospatial clustering and molecular and social epidemiology of drug resistant TB 5K01TW009213-04 10
2012 Geospatial clustering and molecular and social epidemiology of drug resistant TB 7K01TW009213-03 10
2012 Geospatial clustering and molecular and social epidemiology of drug resistant TB 5K01TW009213-02 10
Showing 10 of 11 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK. Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019 Mar 01; 23(3):358-362.View Related Profiles. PMID: 30940300.
     
  2. Bulabula ANH, Nelson JA, Musafiri EM, Machekano R, Sam-Agudu NA, Diacon AH, Shah M, Creswell J, Theron G, Warren RM, Jacobson KR, Chirambiza JP, Kalumuna D, Bisimwa BC, Katoto PDMC, Kaswa MK, Birembano FM, Kitete L, Grobusch MP, Kashongwe ZM, Nachega JB. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study. Clin Infect Dis. 2019 Feb 13. PMID: 30759187.
     
  3. Olson A, Ragan EJ, Nakiyingi L, Lin N, Jacobson KR, Ellner JJ, Manabe YC, Sagar M. Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. J Acquir Immune Defic Syndr. 2018 Nov 01; 79(3):407-411.View Related Profiles. PMID: 30063648.
     
  4. Myers B, Bouton TC, Ragan EJ, White LF, McIlleron H, Theron D, Parry CDH, Horsburgh CR, Warren RM, Jacobson KR. Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. BMC Infect Dis. 2018 Sep 29; 18(1):488.View Related Profiles. PMID: 30268101.
     
  5. McIntosh AI, Jenkins HE, White LF, Barnard M, Thomson DR, Dolby T, Simpson J, Streicher EM, Kleinman MB, Ragan EJ, van Helden PD, Murray MB, Warren RM, Jacobson KR. Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis. PLoS Med. 2018 08; 15(8):e1002638.View Related Profiles. PMID: 30130377.
     
  6. Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK. Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia? Int J Tuberc Lung Dis. 2018 08 01; 22(8):358-362.View Related Profiles. PMID: 29991400.
     
  7. Geadas C, Acuna-Villaorduna C, Mercier G, Kleinman MB, Horsburgh CR, Ellner JJ, Jacobson KR. FDG-PET/CT activity leads to the diagnosis of unsuspected TB: a retrospective study. BMC Res Notes. 2018 Jul 13; 11(1):464.View Related Profiles. PMID: 30001743.
     
  8. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018 04; 6(4):265-275. PMID: 29595509.
     
  9. Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr. 2018 04 01; 77(4):405-412.View Related Profiles. PMID: 29239900.
     
  10. Brooks-Pollock E, Jacobson KR. Rethinking tuberculosis control by targeting previously treated individuals. Lancet Glob Health. 2018 04; 6(4):e361-e362. PMID: 29472017.
     
Showing 10 of 27 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 27 publications over 11 distinct years, with a maximum of 8 publications in 2018

YearPublications
19992
20021
20101
20111
20122
20133
20152
20162
20173
20188
20192
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

alcohol
drug resistant tuberculosis
global health
spatial mapping
tuberculosis
Contact for Mentoring:

771 Albany St
Boston MA 02118
Google Map


Jacobson's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department